IDEAYA Biosciences Price Target Cuts to $45 as Darovasertib Eyes $500M Peak Sales
IDEAYA Biosciences pipeline includes IDE397 and IDE196 in clinical trials and lead asset darovasertib targeting uveal melanoma with potential peak revenue of $500 million. Analyst consensus price target has fallen from $54.67 to $45 in one month, reflecting tempered expectations despite the $3.1 billion valuation and strategic partnerships with Servier and GSK.
1. Clinical Pipeline and Lead Asset
IDEAYA Biosciences is advancing two clinical-stage candidates, IDE397 and IDE196, alongside darovasertib, its lead asset for uveal melanoma which has shown promising Phase 2 results and could drive significant market uptake if pivotal trials succeed.
2. Price Target and Valuation Trends
The consensus analyst price target declined from $54.67 last quarter to $45 this month, aligning with the year-ago level, while the company holds a $3.1 billion valuation reflecting tempered investor expectations.
3. Strategic Partnerships and Revenue Outlook
Collaborations with Servier and GlaxoSmithKline plc support the development of darovasertib and preclinical synthetic lethality programs, and peak revenue for darovasertib is projected to exceed $500 million, offering a potential catalyst for stock valuation.